Haider Afzal, M.D. – FDA Inspection, Oct 4, 2024

Record Details

This FDA Inspection record concerns Haider Afzal, M.D., with an inspection on October 4, 2024, issued by the Dallas District Office, covering human drugs.

Company: Haider Afzal, M.D.
Inspection Date: October 4, 2024
Product Type: Human Drugs
Office: Dallas District Office
Person: Habacuc V. Barrera (Issuing Officer)

View Company Profile

ID · c8a59d7f-73ab-4cdb-b8a4-95d91ec0b74b

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number: 1250905
FDA center: Human Drugs
Project area: Bioresearch Monitoring: Human Drugs
Outcome: Form 483 issued

FDA Citations

21 CFR 312.60FD-1572, protocol compliance
21 CFR 312.60Informed consent
21 CFR 312.62(a)Accountability records

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Haider Afzal, M.D.

FDA Inspection

Haider Afzal, M.D.October 4, 2024